Namsco Corp Ordinary Shares NAMS 深 沪
已收盘 09-19 16:00:00 美东时间
26.69
-0.040
-0.15%
华盛通- 最 高26.88
- 今 开26.82
- 成交量 131.42万股
- 最 低 26.22
- 昨 收 26.73
- 总市值 30.16亿
- 52周最高 27.35
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 14.06
- 委 比 -71.71%
- 总股本 1.13亿
- 历史最高 32.88
- 量 比 1.64
- 振 幅 2.47%
- 历史最低 5.6326
- 每 手 1
- 风险率 4.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wells Fargo Initiates Coverage On NewAmsterdam Pharma Co with Overweight Rating, Announces Price Target of $45
Wells Fargo analyst Yanan Zhu initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Overweight rating and announces Price Target of $45.
08-25 19:27
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
The European Medicines Agency (EMA) has validated the Marketing Authorization Applications (MAAs) for obicetrapib monotherapy and the obicetrapib plus ezetimibe fixed-dose combination (FDC) for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia. NewAmsterdam Pharma, in partnership with Menarini, has submitted these applications, with Menarini responsible for regulatory communications and commercialization in Europe. T...
08-18 12:00
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $39
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $38 to $39.
08-07 23:07
NewAmsterdam Pharma Q2 EPS $(0.15) Beats $(0.46) Estimate, Sales $19.145M Beat $2.235M Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.46) by 67.39 percent. This is a 63.41 percent increase over losses of $(0.41) per share
08-07 05:51
NewAmsterdam Pharma reports Q2 results
NewAmsterdam Pharma press release (NASDAQ:NAMS): Q2 net loss of $17.47M Revenue of $19.15M (+739.9% Y/Y). More on NewAmsterdam Pharma Seeking Alpha’s Quant Rating on NewAmsterdam Pharma Historical ear...
08-06 19:47
'Biotech Says Its Cholesterol Drug Shows Signs Of Preventing Alzheimer's; NewAmsterdam Pharma Hopes Medicine Born Out Of Big Failures May Have An Unexpected Benefit' - STAT News
https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/
07-30 20:25
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
New Amsterdam Pharma will host a conference call and webcast on July 30, 2025, at 10:00 a.m. ET to discuss Alzheimer's Disease biomarker data from the BROADWAY clinical trial. Featured speakers include Philip Scheltens, M.D., Ph.D., Kellyann Niotis, M.D., and Nathaniel Chin, M.D.
07-22 12:00
Goldman Sachs Initiates Coverage On NewAmsterdam Pharma Co with Neutral Rating, Announces Price Target of $27
Goldman Sachs analyst Asad Haider initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral rating and announces Price Target of $27.
07-17 19:21
NewAmsterdam Pharma Updates Employment Agreement with Executive
The latest update is out from NewAmsterdam Pharma Company ( ($NAMS) ). On July ...
07-12 04:48
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
